Omicron variant resembles other respiratory viruses, posing challenges for syndromic surveillance

In an­oth­er sign that bio­phar­ma com­pa­nies are slow­ing their ear­ly R&D ef­forts, Charles Riv­er Lab­o­ra­to­ries is shut­ter­ing more than a dozen sites. The ser­vice provider

GSK’s Blenrep in com­bi­na­tion with two oth­er med­i­cines cut the risk of dis­ease pro­gres­sion or death by 59% com­pared to a stan­dard com­bi­na­tion for mul­ti­ple